Alternate Text DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

SYP-5

  Cat. No.:  DC10436   Featured
Chemical Structure
1384268-04-5
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis.
Cas No.: 1384268-04-5
Synonyms: SYP5; SYP 5
SMILES: O=C(C1=C(O)C(C=CC(C)(C)O2)=C2C=C1)/C=C/C3=CC=CS3
Formula: C18H16O3S
M.Wt: 312.38
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis.
Target: HIF[1]
In Vitro: SYP-5 inhibits hypoxia-induced upregulation of HIF-1. SYP-5 inhibits HIF-1 and downstream gene expression in Hep3B and Bcap37 cells. SYP-5 inhibits tumor cell migration and invasion, as well as tumor angiogenesis, which are mediated by suppressing PI3K/AKT- and MAPK/ERK-dependent HIF-1 pathway. The proteins of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP)-2 that are targets of HIF-1, are down-regulated by SYP-5. SYP-5 displays significant inhibition on hypoxia-induced overexpression of VEGF and MMP2 in both cell lines. In the tube formation assay, SYP-5 suppresses angiogenesis induced by hypoxia and VEGF in vitro. SYP-5 also retards the Hep3B and Bcap37 cells migration and invasion induced by hypoxia and FBS. SYP-5 specifically inhibits hypoxic induction of luciferase expression in U251-HRE but not in U251-pGL3[1].
Cell Assay: The cells (1×105 cells/mL) are seeded into 96-well culture plates. After overnight ncubation, the cells are treated with various concentrations of SYP-5 (2, 10, 50 μM) for 24 h. Then 10μLMTT) solution (2.5 mg/mL in PBS) is added to each well, and the plates are incubated for additional 4 h at 37°C. After centrifugation (2500 rpm, 10 min), the medium containing MTT is aspirated, and 100 μL DMSO is added. The optical density of each well is measured at 570 nm with a SpectraMax Paradigm Reader[1].
References: [1]. Wang LH, et al. SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. Eur J Pharmacol. 2016 Nov 15;791:560-568.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DC47980 HIF-2α-IN-4 HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC50 of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing.
DC41030 1,4-DPCA ethyl ester 1,4-DPCA ethyl ester is the ethyl ester of 1,4-DPCA and can inhibit factor inhibiting HIF (FIH).
DC10436 SYP-5 SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis.
DC9811 PT2399 PT2399(PT=2399) is a novel HIF2α Antagonist.
DC11782 IDF-11774 IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC50 of 3.65 μM.
DC11607 JTZ-951(Enarodustat) A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2.
X